Phaseline

Targets › CDK5

CDK5 (Cyclin-dependent kinase 5): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Mar 2027.

Proline-directed serine/threonine-protein kinase essential for neuronal cell cycle arrest and differentiation and may be involved in apoptotic cell death in neuronal diseases by triggering abortive cell cycle re-entry. Interacts with D1 and D3-type G1 cyclins. (UniProt, Q00535)

Open in Phaseline: the race on CDK5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)Dinaciclib
Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 5 inhibitor
CDK1, CDK2, CDK5, CDK9Phase 2Acral Lentiginous Melanoma; Advanced Malignant Solid NeoplasmMar 2027

Conditions

Acral Lentiginous Melanoma (1) Advanced Malignant Solid Neoplasm (1)

Modalities

small molecule (1)

Companies

National Cancer Institute (NCI) (1)

Related targets

CDK1 (1) CDK2 (1) CDK9 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.